background individuals severe z aat deficiency considerably increased risk developing chronic obstructive lung disease copd hypothesized compensatory increases levels protease inhibitors mitigate effects aat deficiency analysed plasma levels aat act secretory leukocyte protease inhibitor slpi healthy asymptomatic copd subjects aat deficiency methods studied groups included NUMBER asymptomatic subjects zz n NUMBER sz n NUMBER age NUMBER NUMBER identified swedish neonatal screening aat deficiency NUMBER NUMBER controls mm n NUMBER age NUMBER NUMBER older asymptomatic zz n NUMBER healthy mm n NUMBER age NUMBER NUMBER copd patients zz n NUMBER age NUMBER NUMBER mm n NUMBER age NUMBER NUMBER plasma levels slpi aat act analysed using elisa immunoelectrophoresis results significant difference plasma act slpi levels healthy mm zz sz subjects studied groups independent genetic variant subjects copd n NUMBER elevated plasma levels slpi act relative controls n NUMBER NUMBER NUMBER vs NUMBER NUMBER p NUMBER NUMBER NUMBER vs NUMBER NUMBER p NUMBER respectively conclusion findings plasma levels act slpi elevated subjects genetic aat deficiency compared mm controls appear compensate deficiency plasma aat alpha1 antitrypsin alpha1 antichymotrypsin aat deficient age matched ng ml mg ml